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ABSTRACT Heart Failure (HF) diagnosis, subsequent admissions, and possible readmissions present
challenges for health systems worldwide. An increasing number of patients within an ageing population
are surviving cardiac conditions which can leave them with residual heart function impairment. Follow-up
visits of either confirmed HF sufferers or HF high-risk patients could be reduced through the implementation
of Point-of-Care (PoC) measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP), an inactive
signal portion of the active hormone BNP that is released in response to cardiac wall stretch. Serial
measurements of NT-proBNP concentration may serve to indicate progress/deterioration of HF sufferers
which in turn indicates the quality of the interventions designed to treat HF. We present an integrated
PoC solution that involves the user-friendly, low volume sampling of blood directly into a single-use
sampling key with an integral NT-proBNP biomarker detection strip operating on a lateral flow immunoassay
principle. When inserted into a corresponding portable electronic reader it forms an integrated detection
and measurement platform that wirelessly communicates measurements (Wi-Fi) for cloud-based reporting,
trending and data analysis. The system provides a practical, inexpensive support tool for HF management by
informing those involved in clinical decision-making with necessary biomarker data. The PoC NT-proBNP
measurement compares well against alternative technologies based on image analysis.
INDEX TERMS Heart failure interventions, lateral flow immunoassay, low volume blood sampling,
NT-proBNP, point-of-care.
I. INTRODUCTION
Heart failure (HF) refers to the heart failing to pump enough
blood around the body at the right pressure. HF usually occurs
because the heart muscle has become tooweak or stiff to work
properly as a consequence of different cardiac conditions.
HF is a global problem affecting at least 26 million people
worldwide and is increasing in prevalence [1].
Initial insights about HF, and corresponding readmissions,
point to a number of key interventions during follow-ups.
According to the literature [2], [3], the number of HF
readmissions depends directly on the quality of interventions
(or patient management) after the patient is released from the
hospital for primary care. The quality refers to the ‘‘how’’,
‘‘when’’, ‘‘how often’’, ‘‘type of contact’’ provided to the
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patient during the follow-up. These interventions generally
look to ensure the patient is following the treatment, appro-
priately taking medication, making the necessary changes in
lifestyle to keep HF as a chronic illness at bay. Monitoring,
education and training are key practices for the interventions.
Integrated healthcare systems for home-based, point-
of-care (PoC) for monitoring heart failure are recognised
as having a significant future role in the interventions of
heart failure for being cost-effective and reducing patient
readmissions [4]. Currently in the literature, there are many
examples of IoT frameworks and, separately, systems for
integrating information into databases, and also many PoC
diagnostic tools. For example, Spanakis et al. [5] produced
an IoT integrated disease management system, utilising an
alarm based on heart-rate monitoring and blood pressure
using external sensors whilst Jin et al. [6] produced a
neural network-based approach for predicting heart failure
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FIGURE 1. Components for the proposed PoC solution for home monitoring Heart Failure patients: Lateral flow PoC system for measuring NT-proBNP
that transmit values to a server for data storage and data viewer. The server can also send alerts to the physician in charge in order to adjust treatment or
recommend re-admission.
from existing electronic health records taking advantage of
the possibility of analysing time series. In terms of PoC
diagnostic systems of blood-based biomarkers, B-type natri-
uretic peptide (BNP) and NT-proBNP have been identified
as key biomarkers for Heart Failure sufferers [7]–[9]. Both
peptides have an excellent ability to distinguish HF from
non-HF subjects, however some studies have reported that
NT-proBNP may be more useful, owing to a longer half-life
[10]. These biomarkers are released in response to cardiac
wall stretch or pressure overload conditions and shown to be
increased in patients with HF. They are increased in patients
with HF and provide an indication for risk stratification in HF,
which may then be confirmed by echocardiography. If the
level of the biomarker is normal it generally rules out HF
since it exhibits a high negative predictive value of around
99% [9].
There aremany examples of PoC sensing systems designed
for home use, for example DeGregory et al. [11] produced
a rapid PoC diagnostic system for monitoring N-terminal
pro-B-type natriuretic peptide (NT-proBNP) using a low-cost
electrochemical assay, though the dynamic range of their
assay is low compared with the clinically relevant range
(0 to thousands of pg/ml). Further PoC assays exist for
NT-proBNP, based on optical and electrochemical sensors
[12]–[15]. Other methods of assessing heart failure include
monitoring the cardiac pulmonary edema [16] and heart
rate variability [17]. New developments attempt to incor-
porate more sensors and new techniques for processing
the information. Gjoreski et al. [18] present a method for
HF detection based on heart sounds. They combine classic
Machine-Learning and end-to-end Deep Learning applied
to the recorded signals in order to distinguish between
healthy subjects and patients and for the detection of different
HF phases. However at present the currently available
devices in the literature lack integration between the IoT
e-health systems and PoC diagnostics and thus there is
a requirement for a holistic, IoT ‘‘patient-to-cloud’’ based
framework.
The PoC approach presented in this paper allows quan-
titative measurement of NT-proBNP during a home visit
or self-test in contrast to the use of a laboratory by
hospital request. The approach lends itself to being used
to obtain serial measurements of NT-proBNP, with the
cloud-based clinical data viewer enabling the visualisation
of an individual’s biomarker trend over time. We present a
home-based PoC solution for measurement of NT-proBNP,
as a part of follow-up home visits of HF high-risk patients
or for confirmed HF sufferers. The measurements allow for
patient monitoring and trending of NT-proBNP values over
time, and could form an evidence-base for the selection of
appropriate therapeutic interventions. We aim to keep the
advantages of a PoC solution for home use and the possibility
of analysing serial measurements of NT-proBNP. The cost
and assay time of the proposed solution are similar to the one
reported by DeGregory et al. [11] but with an extended range
and accuracy.
The components of the proposed PoC solution for
measuring NT-proBNP for HF are shown in figure 1. The
solution uses a novel, single-use holder containing a blood
sampling port in fluidic connection with an enclosed bespoke
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NT-proBNP lateral flow immunoassay (LFIA) strip. Together
these form the biomarker sampling key. A single analysis
requires that this be inserted into the inexpensive Wi-Fi
enabled electronic ‘biomarker analyser’. The sample required
is about one drop (25µL) of finger-prick blood, and its
collection can be performed in a simple fashion, similar to
a standard diabetes-style personal test kit, either individually
by the patient or during a home-care visit. Placement of
an appropriate quantity of blood onto the blood sampling
port initiates NT-proBNP analysis via passive capillary flow
during which the biomarker analyser takes a reading and
securely transmits this to the data storage server via Wi-Fi.
The entire follow-up can be monitored via a web-based data
viewer or mobile app.
In the subsequent sections of this paper we explain in
detail the components of our solution that includes, a system
for simplified blood sampling, encased lateral flow strips,
the electronic reader, the data storage and display.
II. MATERIALS AND METHODS
A. NATRIURETIC PEPTIDES
BNP and its amino-terminal cleavage fragment, NT-proBNP
are cardiac peptides that have been described as an
‘‘emergency-rescue’’ cardiac hormone against ventricular
overload [19]. The peptides are released (typically in a
1:1 ratio) [20] into plasma in response to excessive stretching
of cardiomyocytes in the ventricular wall. BNP, the active
form of the peptide, acts through the natriuretic peptide
receptor type A causing peripheral vasodilation and a
decrease in blood pressure. While the concentration of each
peptide corresponds to the degree of ventricular stretching,
it has been shown that the NT-proBNP form exhibits a ∼ 6×
longer plasma half-life and so measured levels may appear to
be higher [21].
On an individual basis, measured levels of NT-ProBNP/
BNP vary each day suggesting that the peptides function
as continuous and sensitive markers of ventricular stress.
Several drugs used to treat heart failure (i.e. angiotensin
converting enzyme -ACE- inhibitors, angiotensin receptor
blockers, aldosterone antagonists, beta-blockers) have been
shown to decrease circulating concentrations of natriuretic
peptides including NT-proBNP [22], with lower peptide
levels corresponding to an improved prognostic outcome.
Furthermore, in some cases, it has been shown that peptide
levels precede felt symptoms of worsening pulmonary
congestion, such as breathlessness and weight gain. It has
therefore been proposed that BNP levels can be used to guide
treatment of heart failure [9].
Maisel et al. [8] have proposed thresholds in the level
of NT-proBNP for ruling-in and ruling-out patients with
suspected heart failure. For patients aged <50, the cut-off
point is 450 pg/ml, for those aged 50 to 75, the cut-off is
900 pg/ml, and is 1800 pg/ml for those aged >75. We stress
that for an initial heart failure diagnosis, this primary rule-in
or rule-out needs to be performed in a clinical setting, along
with other measurements (for example if injection fraction
measured using echocardiography is below 40% [23], body
measurements, etc). Our home-based PoC system is intended
as a tool for further regular monitoring of NT-proBNP values,
and trending over time, in order to guide treatment and
recovery.
B. PREPARATION OF CARBON-BASED NT-proBNP
DETECTION CONJUGATES
1) PRINCIPLE OF LATERAL FLOW SENSING
Here we present the design and implementation of our LFIA
for NT-proBNP sensing. Lateral flow immunoassays have a
number of advantages over laboratory assays for use at point-
of-care. They are inexpensive, have a long shelf life and have
a simple operational procedure when compared to typical
biomarker measurement tests such as the enzyme-linked
immunosorbent assay (ELISA). The principle of LFIAs has
been well reviewed by Koczula et al. [24], thus we present
only a brief overview here. Initially, biomarkers in fluid form
(in our case: blood, which flows directly from the capillary
channel of the biomarker sampling key, but this can be also
plasma, serum, urine, etc.) are introduced into the absorbent
pad. The pads are all porous and hydrophilic, and thus liquids
are passively ‘pumped’ through the strip by capillary flow.
The applied fluid will flow into the conjugation pad, where
biomarkers can interact with conjugate labels, in our case
these are amorphous carbon nanoparticles (AC-NPs). The
liquid then flows into a nitrocellulose reaction membrane,
in which there is a ‘test line’ printed. The test line is printed
with antibodies which are reactive to the AC-NP-labelled
antigens. As the number of AC-NPs which react, and bind,
to the antibody test line is a function of the concentration of
biomarkers in the blood, the optical intensity of this line may
be used to transduce the biomarker concentration.
2) REAGENTS / AB / CONJUGATION PROTOCOL
The detection of NT-proBNP in blood samples was achieved
using a bespoke LFIA developed for use with our biomarker
analyser. The LFIA employs AC-NPs that act as high-contrast
optical detection labels via a functionalisation step involving
their conjugation to an NT-proBNP specific detection anti-
body. The capillary flow of fluid samples over time causes
the accumulation of functionalised detection labels on the test
line zone of the lateral flow membrane. The accumulation
of functionalised AC-NPs varies with the concentration of
NT-proBNP in the sample. This has been optimised for the
clinically-relevant range of 30-1360 pg/ml of NT-proBNP.
The integration of the LFIA with the housing permits direct
connection of LFIAwith the blood sampling capillary, as well
as mechanical alignment with the optical detection portion of
the biomarker analyser. The biomarker analyser measures the
increase in light absorption caused by accumulating carbon
labels.
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3) CARBON NANOPARTICLE TO ANTIBODY CONJUGATION
Conjugation of antibody to carbon was achieved via a
modification of a previously described physical adsorption
technique [25]. Briefly; 1ml of 5mM Borate buffer (pH
8.8), containing 140 µg of 15F11 Anti-proBNP antibody
(Abcam, Cambridge, UK) was added to 2mg of Carbon black
nanoparticles (Alfa Aesar, Lancashire, UK) with sonication
for a total of 60 seconds (Branson Sonifier 250). Sonication
was maintained over an ice bath at a maximum of 50 W
power to avoid thermally induced damage to the antibody
conjugate. A deep black suspension of colloidal carbon
moderately stabilized by the adsorbed antibodies is formed.
The suspension was then incubated with gentle agitation at
4◦C for a further 18-hour period.
The conjugate was then centrifuged at 16000g for
15 minutes. After removal of the supernatant, the pellet was
resuspended in 1ml of a wash buffer comprising 5mMBorate
buffer (pH 8.8), containing 0.5% BSA (w/v). Further 1-hour
incubation with gentle agitation (4◦C) was used to complete
blocking of any remaining adsorption sites on the AC-NPs.
Centrifugation was repeated twice more, and the resulting
stably passivated colloidal carbon conjugate suspended in a
storage buffer comprising 100 mMBorate (pH 8.8) and 0.5%
(w/v) BSA. This was stored at 4◦C.
4) ASSEMBLY AND CALIBRATION OF 24E11-CNP LATERAL
FLOW TEST STRIP
The XYZ3060 Dispense Platform (Biodot Ltd) was used to
quantitatively dispense the NT-proBNP detection conjugate
(1:30 dilution at 10µl/cm) onto the Ahlstrom 6613H conju-
gate release pad material. Similarly, a 0.5 mm wide test line
of 24E11 anti-NT-proBNP antibody was deposited (1µl/cm
at 0.5mg/ml) onto Sartorius UniSart CN95 cellulose nitrate
membrane at an optimal width for alignment with the optical
detector in the biomarker analyser. Dispensed reagents were
dried at 37◦C for 2 hours, prior to immediate assembly
into 300mm wide ‘‘panels’’ with the addition of sample
and absorbent pad materials. Panels comprised a backing
substrate bearing a pressure-sensitive adhesive to which the
conjugate pad (Ahlstrom 6613H), cellulose nitrate membrane
(Sartorius UniSart CN95) and absorbent pad (Ahlstrom 222)
were fixed in the overlapping arrangement common to LFIA
strips [26]. This arrangement enables the sequential transfer
of applied biosample by capillary action through the various
zones of the test strip. Individual strips (4 mm wide) were
cut from panels using a guillotine (Rexel ClassicCut CL410)
and immediately transferred into prepared strip holders. Such
populated strip holders were then sealed into foil pouches
with desiccant to maintain humidity below 10% during
storage. For low volume sampling, the channel, sampling pad
and conjugate pad of each strip were then etched to a width
of 1.5 mm using a CO2 laser (Universal VLS 230) [27].
We calibrated the NT-proBNP test strips using a dilution
series of NT-proBNP in negative control serum to establish
FIGURE 2. The calibration curve of negative control serum spiked with
human NT-proBNP in the range of 30 to 1360 pg/ml.
a calibration curve from a range of 30 to 1360 pg/ml.
We note that the clinical range of NT-proBNP extends
beyond this range [23] however, at present we have been
limited by the maximum level of NT-proBNP patient sample
available to us. Given the lack of an accepted NT-proBNP
reference standard [28] we elected to produce an internal
standard containing native human NT-proBNP in a serum
matrix. The use of several samples in a pool increases
the potential representation of multiple uncharacterized
NT-proBNP proforms and glycosylation states [29]. Patient
samples containing NT-proBNP >1000 pg/ml (via Roche
Cobas e411 analysis) were mixed in equal proportion to
form a pooled sample (average 1360pg/ml NT-proBNP). This
was used to create calibration standards by dilution of the
pooled sample into a pooled ‘normal human’ control serum
(NT-proBNP < 50 pg/ml).
We measure the absorbance of the test strip in two
locations, (i) at the test line and (ii) the background
(blank area) of the test strip using the biomarker analyser,
as explained in greater detail in the hardware section II-D1.
We then use the ratio of the optical absorbance of the test line
and background, which helps to overcome any heterogeneity
in the test strip background [30]. The calibration curve,
test/background ratio R against NT-proBNP concentration C,
with a goodness of fit (R2) equals 0.9966 as is shown
in figure 2. The calibration curve was modelled as a linear
fit as equation (1):
C = 6174R+ 5775.2 (1)
The average coefficient of variation (CV) of the calibration
curve is 1.6% which compares favourably to similar LFIA
NT-proBNP tests [31]. The combination of low CV and linear
response of the sensor in the tested range (30 to 1360 pg/ml)
demonstrate a clear ability to accurately detect NT-proBNP
for HF patients.
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C. LOW VOLUME BLOOD SAMPLING
Here we present the design and fabrication of our biomarker
sampling key, used for obtaining and transferring a blood
sample for use in the biomarker analyser. This section details
how blood samples will be taken in future medical trials
and by patients at home, we stress that our present work
uses human clinical plasma samples. The intended use of
the biomarker sampling key is a simple, inexpensive tool
for collecting a finger-prick blood sample, without training
or the need of a healthcare worker. For a PoC system,
the preferred source of patient’s blood is finger-prick blood,
since venous-draw blood needs to be collected by a nurse
or phlebotomist, which can be a source of distress [32]. Our
previous experience in using PoC diagnostics for measure-
ment of blood-based biomarkers (particularly in the global
diagnostic Qualcomm Tricorder XPRIZE competition [33])
demonstrated that the user experience must be improved if
PoC diagnostics are to find widespread use, especially for
more elderly patients. Our design has the following features:
(i) the patient should be able to use the system, alone,
without the need of a healthcare worker, and by using
a standard commercial blood collecting lancet.
(ii) the required blood volume is low (<25µL), as this is
the average amount of blood that can be comfortably
obtained [34].
(iii) external pipettes and capillary tubes (especially those
requiring the use of one hand to extract blood from the
other) require a high level of dexterity and need not be
used. Blood is introduced directly from one finger into
the device.
(iv) sampling is rapid thereby reducing discomfort.
1) POLYMER HOUSING FOR THE LATERAL-FLOW ASSAY
The basic design of the biomarker sampling key is of a
polymer housing which includes a 25µL capillary channel,
in fluidic connection with an enclosed LFIA test strip.
This ‘single-use’ assembly must be placed directly into the
biomarker analyser, ready for the addition of a blood sample
and subsequent analysis. The key is constructed from two
polymer pieces as shown in figure 3(a) and has a hydrophilic
cover tape (ARCARE 93049 hydrophilic pressure-sensitive
adhesive), over the channel to aid wicking. The principle is
that, initially, a blood drop is obtained on the finger, using
a standard lancet and then rapidly wicked from the patient’s
finger, directly into the capillary channel, figure 3(b-c).
Secondly, when the required volume is full; the entire blood
volume drains into the NT-proBNP LFIA. The channel outlet
is in direct physical contact with the LFIA sample pad as
shown in figure 3(d). This can be performed in one drop or
in several small drops according to which is easier for the
patient. The test is then completed and a measurement is
obtained by the biomarker analyser. The main design features
of the device are described in the following paragraphs.
The required volume of blood required in most of the avail-
able PoC NT-proBNP test kits varies from 70 to 150µL [35].
FIGURE 3. (a) photograph of the biomarker sampling key with top,
bottom pieces and LFIA, (b) patient starts to sample blood (c) blood is
rapidly wicked into the channel (d) when full, the blood rapidly drains
into the LFIA for measurement.
We have reduced the required volume in our LFIA by
minimising the physical width of the test strip. The typical
width of a commercial lateral flow assay is between 4 to
5 mm which is needed to help facilitate reading by eye.
We have, however, designed our strips as 1.5 mm wide,
for opto-electronic measurement which can be successfully
performed with 25µL of whole blood. Minimising the time
taken to introduce the blood sample into the test, through the
use of highly ‘wicking’ capillary action helps to reduce the
likelihood of blood spills. To draw blood by capillary action
the capillary channel must have both a capillary length below
that of blood, and a positive surface energy force. This has
been achieved by ensuring that the diameter of the blood
collection channel is below the capillary length λc [36] of
blood calculated as:
λc =
√
γ /(ρg) (2)
where γ is the surface tension of blood (∼ 55.9mNm−1) [37],
ρ is the density of blood (1060kg m−3) [38] and g is
the acceleration due to gravity; thus the capillary length
is ∼2.3 mm and the channel height is set as 1.5mm. The
capillary force is calculated as [36]:
Fγ = wγ (cos θ2 + cos θ1)+ 2hγ (cos θ1) (3)
where θ1 is the contact angle between blood and the three
3D-printed walls, θ2 is the contact angle between blood
and the top surface, w is the channel width and h is the
channel height. The value of θ1 is ∼ 69◦ (measured using
KSV Instruments LTD Cam200 contact angle meter) and by
using a hydrophilic, biologically compatible adhesive tape,
the contact angle of the top surface, θ2 is much lower at∼ 25◦.
The surface energy force is thus highly positive and provides
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rapid wicking. After the channel is filled, the blood quickly
and fully drains into the sampling pad of the LFIA which will
reach completion without further user intervention by relying
on passive capillary flow. The result is a test line of variable
density which is measured by the biomarker analyser.
D. BIOMARKER ANALYSER
1) HARDWARE
The principle of the biomarker analyser is to measure the
optical absorbance of the LFIA at the test line and divide
this value by the optical absorbance at the LFIA background.
Our embedded system consists of a microcontroller, light
emitting diodes, optical sensors, and a Wi-Fi module for
data transmission. We used two small PCBs, the first
includes 2 LEDs (LED PCB) for illuminating the LFIA and
the second includes 2 ambient light sensors (ALS PCB) for
measuring absorbance, as shown in figure 4(a) which shows
the optical layout of the lateral flow strip reader used to
quantify the NT-proBNP concentration in the blood sample.
In the biomarker analyser, two green (525nm) LEDs (Würth
Elektronik) have been used as optical illuminating sources.
One LED is positioned directly above the test line and
the second LED is used to illuminate a blank, ‘background’
section of the LFIA.
FIGURE 4. (a) Block diagram of the electronic circuit. (b) Optical layout of
the strip reader. Two LEDs are used to illuminate the control and test line
with an ALS under each line to measure the optical intensity after passing
through the biomarker sampling key.
In our system, 2 ambient light APDS 9301 sensors (Avago
Technologies) were used for light detection. This ALS
contains two integrating analog-to-digital converters (ADC)
that digitise and integrate the currents from two photodiodes.
Two integrating ADCs convert the photodiode currents to
a digital output that represents the irradiance measured on
each channel. The light intensity to digital signal output
capable of direct I2C interface. This digital input is used in
a microcontroller to calculate the NT-proBNP concentration
in the sample using equation (1). Two ALS have been placed
on the ALS PCB and aligned to the two LEDs on the
LED PCB, as shown in figure 4(b). The biomarker analyser
microcontroller is a Particle Photon board (Wurth Elektronik)
that combines an ARM Cortex M3 microcontroller with a
Broadcom Wi-Fi chip. A lithium-ion battery, which may
be charged using the battery shield, enables the biomarker
analyser to be used portably.
ALS 1 is located directly below the test line (7 mm
separation) and measures the intensity at the carbon line
illuminated by the corresponding LED. The separation
between the LED and the test line is 3 mm. The LED
illuminates the line and the AC-NP absorbs the photons and
subsequently reduces the intensity measured by the ALS.
The AC-NP that binds at the test line results in a darker
line, with increased optical absorbance. Since the density of
the test line is related to the number of AC-NP attached to
the NT-proBNP, the optical intensity is used to measure the
quantity of the NT-proBNP present in the sample.
ALS 2 is used to measure the absorption of the LED light
through the LFIA and it is used as a backgroundmeasurement
for the ratio of test line divided by background measurement.
2) FIRMWARE
The firmware was uploaded to the Particle Photon board via
theWi-Fi network. The Particle Photon board enables updates
to the firmware via a Wi-Fi network.
The firmware tasks can be broken into:
1) Control the illumination of the two LEDs
2) Control the gain and integration time of the sensors
3) Collect the digitised sensor measurements
4) Transmit the measurements to the web-based
dashboard
The input voltage used to turn the LEDs on and off is
supplied by the Particle board which in turn collects the
sensor measurements every 5s. Each sensor measurements
extracted from the I2C communication line is transmitted via
Wi-Fi to the private server for viewing and analysis.
E. WEB-BASED DASHBOARD FOR MONITORING
Initial insights about HF point to key interventions during
follow-ups to provide better care and for avoiding re-
admissions. We have adopted and extended a data model
initially developed for an outpatient clinic for heart failure
patients at the Academic Medical Center (AMC) in Amster-
dam, The Netherlands [39] to capture the different practices,
medications, and data in general about Heart Failure and the
key interventions. We extended the model in order to capture
data from the proposed PoC solution.
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The solution presented in this paper focuses on interven-
tions where a PoC device is used during a medical visit to
the patient’s home, or for self-use. NT-proBNP is measured
and monitored through consecutive visits. The progression of
NT-proBNP serves as an indication of patient response to the
treatment and also serves as a deciding factor for considering
readmission.
Measured values of NT-proBNP are sent via Wi-Fi to the
data storage server and they can be viewed in the web-based
data viewer or mobile app. Figure 5(a) shows a screen in the
web-based system for monitoring NT-proBNP. The system
also is capable of sending alarms for risk analysis based
on the proposed algorithm based on changes in consecutive
concentrations of NT-proBNP 5(b).
FIGURE 5. (a) Screen from a web-based system to monitor the
progression of NT-proBNP during a hypothetical patient’s follow-up.
(b) An algorithm for home monitoring of NT-proBNP on discharged HF
sufferers. T1 and T2 are thresholds for relative and absolute changes on
the biomarker.
III. RESULTS
A. COMPARISON OF THE MEASUREMENTS
To compare the result of the ALS to a standard method of
measuring LFIA test results, we used a flatbed scanner (HP
OFFICEJET PRO 8600, 1200 DPI) to image the test strips
(which had been removed from the biomarker key).
We used ImageJ [40] for analysing scanned images of
the test strips. For each LFIA test strip, a selection box of
defined size was manually centered over the LFIAmembrane
corresponding to the test line region. The ‘Profile-plot’ tool
was used to measure the peak amplitude of the test line in
greyscale values with reference to the background greyscale
value of the non-test line region of the membrane.
FIGURE 6. Comparison curve between the measured values of 12 LFIA
patient samples, as measured using ImageJ image analysis from a
scanned image, and the biomarker analyser ALS-based measured value.
This is an established method for deriving a quantitative
output from LFIA test strips [41]–[43]. Its previous and
common usage makes it useful as a ‘reference’ measurement
method to which we can compare results from the biomarker
analyser.
Image analysis using ImageJ is a technical procedure
that requires some level of training and skill. Meanwhile,
the biomarker analyser is designed and programmed for
home-based use with minimal training; such that patient need
only (i) insert biomarker sampling key and (ii) provide a
blood sample.
A plot of the measurement of 12 patient samples obtained
from both the Image analysis and the biomarker analyser
is shown in figure 6. The results show a close trend, with
the accuracy of each measurement system of a similar
order: the average coefficient of variation (CV) of results
(triplicate sets of LFIA tested at each concentration for
the biomarker analyser is 7.8% versus 7.3% for ImageJ.
Some of the heterogeneity in measurement derives from
defects in the optical quality of the test line (for example,
variation caused by unequal fluid flow [44]). It should be
also noted that our conjugate antibody was the ‘24E11’
antibody which recognises a.a. 61-76 of NT-proBNP and
the test line antibody was the 15F11 which recognises a.a.
13-27 of NT-proBNP. Neither of these regions appears to be
affected by glycosylation [45], [46] whereas the Roche assay
does appear to be affected by the glycosylation status of the
particular patient sample [47]. Thus in future testing our PoC
assay will be cross-correlated against further commercial
NT-proBNP assays.
The same 12 patients NT-proBNP plasma samples
(x˜i i = 1..12) were measured using LFIA test strips used
with the biomarker sampling key and biomarker analyser PoC
device andwere comparedwith their corresponding reference
values extracted from the image analysis (xi i = 1..12)
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FIGURE 7. Bland-Altman plot for 12 pairs of measurements of NT-proBNP. The reference values from Image J analysis are compared to the PoC
solution reported in this paper. The average difference d¯ is 24.58 pg/ml, the lower and upper limit of the confidence interval at 95% for the
differences are −138.42 and 187.58 pg/ml respectively which are delimited by the dotted red lines. These limits also define the Limits of
Agreement (LoA) and the seen differences are expected to be confined to them and not to exceed the maximum allowed clinical deviation.
However, the differences could be inside the envelope provided by the outmost limits given by the confidence intervals of the LoA plotted in blue.
Additionally, the confidence interval at 95% for the mean difference is indicated in green lines; † for the upper limit and § for the lower limit.
independently performed on the scanned image of the LFIA.
A Bland-Altman plot [48] was generated using the 12 pairs of
measurements and it is shown in figure 7. The range of values
covers values fromHF sufferers and normal individuals. Each
point in the plot has coordinates (ai, di) where the average
of the two measurements (ai = (xi + x˜i)/2) goes in the
horizontal axis and the difference (di = xi − x˜i) is located
in the vertical axis. For the analysed data, the average of
the differences d¯ = ∑12i=1 di /12 is 24.58 meaning that
the PoC values (x˜i) are in general 24.58 pg/ml below the
reference value (xi). This offset could be corrected by just
adding 24.58 to the PoC values. The standard deviation of
the differences (according to sd =
√∑12
i=1(di − d¯)2 /11)
is 83.16. The confidence interval at 95% for the differences
(d¯±1.96sd) is used as a tool for verifying agreement between
the measurements. It is, however, important to additionally
check for any obvious skew and ultimately to demonstrate
clinical agreement. At this time, a true estimation of limit
of detection or quantification has not been made as we have
focused on the trending performance for patients who are
clearly suffering from heart failure and have significantly
elevated levels of NT-proBNP.
IV. DISCUSSION
In this paper, we have aimed to present a PoC solution that
can aid in the treatment and care of HF patients through
the use of a novel diagnostic system based on NT-proBNP
LFIA. A key driving force in this work has been to produce
a reliable system that can be used without supervision, and
with minimal discomfort. Commercial portable PoC systems
are available, for example, the Roche cobas h 232 POC
system but this is intended for pre-hospital and emergency
room, rather than home-based settings. For example, the most
widely used home-based diagnostic kits worldwide are
blood-based glucose testing for diabetes patients [49]. The
success of diabetes testing is that is simple and relatively pain-
free, and the volume of blood need not be tightly measured
by the user. The level of discomfort is minimised by enabling
testing with one drop of blood. In contrast, lateral flow
immunoassay-based testing typically requires several blood
drops which is very off-putting for the patient. This system
tries to address this issue of usability by reducing the blood
volume down to a minimum and by automatically measuring
blood volume by means of filling a capillary channel.
We present results of the concentration of NT-proBNP
measured by our PoC solution compared to the ImageJ
method. The two methods do not replace the validated Roche
analyser (or similar lab-based analysers) for NT-proBNP
currently used in many hospital labs. However, the biomarker
analyser is a simplification of a quantitative method offered
by image analysis aimed for home use. It can give an account
of changes on the concentration of NT-proBNP that can be
an indication of adherence to the treatment or could raise
a flag for a possible readmission if required. For example,
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a 2015 study on the serial measurement of NT-proBNP in
patients with stable coronary heart disease showed that, after
12 months, an increase in NT-proBNP levels was associated
with increased risk of subsequent cardiovascular event [50].
Furthermore, Masson et al. [51] showed that NT-proBNP
levels measured at time periods of 4-month intervals enabled
greater risk stratification for HF patients, whilst Pascual-Figal
et al. [23] showed that changes in NT-proBNP level were
predictive of subsequent cardiovascular events in HF patients
after a period of 2 weeks to 6 months. NT-proBNP levels
need to be carefully interpreted in elderly patients with
comorbidities, who may have elevated NT-proBNP levels
without having HF [52]. We emphasise that this is an
additional tool for HF monitoring, on a case-by-case basis,
and not intended for diagnosis of HF.
It can be observed that the 12 points of the Bland-Altman
plot in figure 7 are well contained within the confidence
interval at 95% (LoA) for the differences and the points
uniformly spread up and down from the horizontal line
defined by the average of differences d¯ along with the
range of values. No systematic skew is seen and the
possible offset can be removed to bring the mean difference
to zero. Guidelines suggest that, in serial measurements,
a practical threshold of a 30% variation in the measured
value of NT-proBNP over time is indicative of a clinically
relevant change [53]. Thus, for a patient with elevated (above
450 pg/ml [8]), the sensitivity of our PoC system suggests
that this could become a clinically useful tool, though we
stress the need for further testing with patients.We present the
framework in figure 5(b) for serial monitoring of NT-proBNP
levels over time, and how increased values of the biomarker
may be used as an alarm to readmit patients to hospitals or
to readjust the treatment. The low CV and linearity of the
LFIA test (as shown in figure 2) and the linear response of the
biomarker analyser relative to the standard ImageJ analysis,
figure 6, show that clinically relevant changes in NT-proBNP
measurements would be detectable with our system.
It is understood that the system is intended mainly
for already diagnosed HF-sufferers and the algorithm as
presented in figure 5(b) serves as an example for the aim
and it would require data collected and validated to tune the
thresholds and parameters involved. The framework proposes
two thresholds: T1, for the rate of change of NT-proBNP
with time, and T2 for the absolute value of NT-proBNP,
as proposed by Maisel et al. [8]. When both T1 and T2 fall
below the threshold levels, this would be indicative of patient
improvement whilst values further increasing above these
thresholds would indicate deterioration and may signify the
requirement for further treatment. This paper has set out the
framework for how our PoC will be used. Future ongoing
work will aim to show the system in a clinical setting.
V. CONCLUSION
The presented PoC solution has shown promise in being
adopted for routine follow-up medical visits for HF sufferers
and for HF high-risk patients.
The home-based biomarker analyser and blood sampling
key enable the measurement and monitoring of a patient’s
progress and may help in the decision for readmission,
or changes in treatment. Early warnings in non-adherence
with the treatment reflected by significant increases of the
biomarker, may improve patient management and conse-
quently reduce hospital readmissions.
The low-cost solution is relatively easy to operate after
minimal training and requires no specialist equipment.
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